Related Experiment Video
Updated: Aug 8, 2026
Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
Published on: February 10, 2013
Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor
W J Koch1, H A Rockman, P Samama
1Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
Transgenic mice were created with cardiac-specific overexpression of the beta-adrenergic receptor kinase-1 (beta ARK1) or a beta ARK inhibitor. Animals overexpressing beta ARK1 demonstrated attenuation of isoproterenol-stimulated left ventricular contractility in vivo, dampening of myocardial adenylyl cyclase activity, and reduced functional coupling of beta-adrenergic receptors. Conversely, mice expressing the beta ARK inhibitor displayed enhanced cardiac contractility in vivo with or without isoproterenol. These animals demonstrate the important role of beta ARK in modulating in vivo myocardial function. Because increased amounts of beta ARK1 and diminished cardiac beta-adrenergic responsiveness characterize heart failure, these animals may provide experimental models to study the role of beta ARK in heart disease.
Insights
Beta-adrenergic receptor kinase-1 (beta ARK1) plays a key role in heart function. Inhibiting beta ARK1 enhances cardiac contractility, suggesting its role in heart disease models.
Area of Science:
- Cardiovascular Physiology
- Molecular Cardiology
- Transgenic Animal Models
Background:
- Beta-adrenergic receptor kinase-1 (beta ARK1) is implicated in regulating cardiac function.
- Dysregulation of beta ARK1 activity is observed in heart failure.
- Understanding beta ARK1's role is crucial for developing heart disease therapies.
Purpose of the Study:
- To investigate the in vivo role of beta ARK1 in cardiac function using transgenic mouse models.
- To determine the effects of beta ARK1 overexpression and inhibition on myocardial contractility and signaling.
Main Methods:
- Generation of transgenic mice with cardiac-specific overexpression of beta ARK1 or a beta ARK inhibitor.
- Assessment of left ventricular contractility in vivo using isoproterenol stimulation.
- Measurement of myocardial adenylyl cyclase activity and beta-adrenergic receptor coupling.
Main Results:
- Overexpression of beta ARK1 attenuated isoproterenol-stimulated contractility and reduced beta-adrenergic receptor function.
- Inhibition of beta ARK1 enhanced cardiac contractility, both with and without isoproterenol.
- These findings highlight beta ARK's critical role in modulating myocardial function.
Conclusions:
- Transgenic models of beta ARK1 modulation provide valuable insights into cardiac regulation.
- Beta ARK1 activity is a significant determinant of in vivo cardiac performance.
- These models may serve as platforms for studying beta ARK1's contribution to heart failure pathogenesis.
